Hepatitis C Virus Infection
The indications for apheresis are hepatitis C virus (HCV) serotype 1 cases with HCV-RNA more than 100 kIU/mL and interferon-α (IFN) resistive.
Plasma fractionator (2nd filter) of double filtration plasmapheresis (DFPP) is equivalent to Cascadeflo™ EC-50 W with a size pore of 30 nm.
Immediately after DFPP, HCV starts showing a rebound phenomenon. The timing of IFN administration has to be as soon as possible.
When patients have a history of splenectomy, catheter infection tends to cause severe septicemia.
KeywordsSustain Virological Response Fibrinogen Level Rebound Phenomenon High Sustain Virological Response Virus Removal
- 2.Yamashita T, Arai K, Sakai A, Mizukoshi E, Sakai Y, Kagaya T, Nakamoto Y, Honda M, Wada T, Yokoyama H, Kaneko S (2006) Virological effects and safety of combined double filtration plasmapheresis (DFPP) and interferon therapy in patients with chronic hepatitis C: a preliminary study. Hepatol Res 36:167–175PubMedCrossRefGoogle Scholar
- 3.Fujiwara K, Kaneko S, Kakumu S, Sata M, Hige S, Tomita E, Mochida S (2007) Virus Reduction Therapy Study Group: Double filtration plasmapheresis and interferon combination therapy for chronic hepatitis C patients with genotype 1 and high viral load. Hepatol Res 37:701–710PubMedCrossRefGoogle Scholar